Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Dec 16:19:100360.
doi: 10.1016/j.lrr.2022.100360. eCollection 2023.

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)

Jumoke Okikiolu  1 , Claire Woodley  1 , Llywelyn Cadman-Davies  1 , Jennifer O'Sullivan  1 , Deepti Radia  1 , Natalia Curto Garcia  1 , Patrick Harrington  1 , Shahram Kordasti  1   2 , Susan Asirvatham  1 , Priya Sriskandarajah  1 , Jamie Saunders  1 , Chandan Saha  1 , Irene Sanchez  1 , Hugues deLavallade  1 , Donal P McLornan  1 , Claire N Harrison  1
Affiliations
Case Reports

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)

Jumoke Okikiolu et al. Leuk Res Rep. .

Abstract

Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by the European Medicine Authority (EMA) for treatment of Polycythaemia Vera (PV) following a Phase III trial (PROUD-PV / CONTINUATION-PV). FDA approval for PV, regardless of treatment history, was subsequently granted in November 2021. We hereby demonstrate the safety and tolerability of ropegIFN in a series of MPN patients at variable doses. It corroborates reports of efficacy of ropegIFN in patients with PV and use in pregnancy.

Keywords: Essential Thrombocythaemia; IFN; MPN; Polycythaemia Vera.

PubMed Disclaimer

Conflict of interest statement

Patrick Harrington: research funding from Bristol Myers Squibb, Honoraria and 10.13039/100017655Incyte. Claire N. Harrison: Advisory board and speaker fees: AOP and Roche.

Figures

Fig 1
Fig. 1
Haematological response in RopegIFN treated patients, x axis represents the time in months following the initiation of ropegIFN treatment A) Platelet count response to RopegIFN and in case 1 from 5 months, platelet count response to ANA B) WCC response to RopegIFN in case 5.
See this image and copyright information in PMC

References

    1. Kiladjian J.J., Giraudier S., Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia. 2016;30(4):776–781. doi: 10.1038/leu.2015.326. - DOI - PubMed
    1. How J., Hobbs G. Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature. Cancers (Basel). 2020;12(7):1–13. doi:10.3390/cancers12071954. - PMC - PubMed
    1. Gisslinger H., Klade C., Georgiev P., et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and continuation-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3) doi: 10.1016/S2352-3026(19)30236-4. - DOI - PubMed
    1. Gisslinger Heinz, Klade Christoph, Georgiev Pencho, Krochmalczyk Dorota, Gercheva-Kyuchukova Liana, Egyed Miklos, Dulicek Petr, Illés Árpád, Pylypenko Halyna, Sivcheva Lylia, Jiří Mayer11 P. Long-term use of ropeginterferon alpha-2b in polycythemia vera: 5-year results from a randomized controlled study and its extension. Am. Soc. Haematol. 2020 https://ash.confex.com/ash/2020/webprogram/Paper136973.html MD1*PhD2*MD3*MD4*MD5*MD6*MD7*MDPhD8*MD9*MD10* Published.
    1. Barbui T., Vannucchi A.M., De Stefano V., et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8(3) doi: 10.1016/S2352-3026(20)30373-2. - DOI - PubMed

Publication types